{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T01:37:37Z","timestamp":1768268257597,"version":"3.49.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1016\/j.ejphar.2015.02.009","type":"journal-article","created":{"date-parts":[[2015,2,18]],"date-time":"2015-02-18T20:46:27Z","timestamp":1424292387000},"page":"19-24","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":95,"special_numbering":"C","title":["Ipragliflozin, an SGLT2 inhibitor, exhibits a prophylactic effect on hepatic steatosis and fibrosis induced by choline-deficient l-amino acid-defined diet in rats"],"prefix":"10.1016","volume":"754","author":[{"given":"Yuka","family":"Hayashizaki-Someya","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiji","family":"Kurosaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiyuki","family":"Takasu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hikaru","family":"Mitori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunji","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kumi","family":"Koide","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoji","family":"Takakura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2015.02.009_bib1","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1111\/hepr.12081","article-title":"Direct renin inhibitor, aliskiren, attenuates the progression of non-alcoholic steatohepatitis in the rat model","volume":"43","author":"Aihara","year":"2013","journal-title":"Hepatol. Res."},{"key":"10.1016\/j.ejphar.2015.02.009_bib2","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/j.metabol.2008.06.017","article-title":"Diazoxide enhances basal metabolic rate and fat oxidation in obese Zucker rats","volume":"57","author":"Alemzadeh","year":"2008","journal-title":"Metabolism"},{"key":"10.1016\/j.ejphar.2015.02.009_bib3","first-page":"BR439","article-title":"Diazoxide attenuates insulin secretion and hepatic lipogenesis in zucker diabetic fatty rats","volume":"11","author":"Alemzadeh","year":"2005","journal-title":"Med. Sci. Monit."},{"key":"10.1016\/j.ejphar.2015.02.009_bib4","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1056\/NEJMoa060326","article-title":"A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis","volume":"355","author":"Belfort","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2015.02.009_bib5","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1111\/j.1572-0241.1999.01377.x","article-title":"Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions","volume":"94","author":"Brunt","year":"1999","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.ejphar.2015.02.009_bib6","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nrd3180","article-title":"SGLT2 inhibition\u2014a novel strategy for diabetes treatment","volume":"9","author":"Chao","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejphar.2015.02.009_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cld.2013.09.019","article-title":"Obesity and liver disease: the epidemic of the twenty-first century","volume":"18","author":"Corey","year":"2014","journal-title":"Clin. Liver Dis."},{"key":"10.1016\/j.ejphar.2015.02.009_bib8","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.4049\/jimmunol.168.6.2795","article-title":"Regulation of cytokine expression by ligands of peroxisome proliferator activated receptors","volume":"168","author":"Cunard","year":"2002","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejphar.2015.02.009_bib9","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1053\/bega.2002.0333","article-title":"Pathogenesis of steatohepatitis","volume":"16","author":"Day","year":"2002","journal-title":"Best Pract. Res. Clin. Gastroenterol."},{"key":"10.1016\/j.ejphar.2015.02.009_bib10","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/0009-8981(80)90192-8","article-title":"Modified assay for determination of hydroxyproline in a tissue hydrolyzate","volume":"104","author":"Edwards","year":"1980","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.ejphar.2015.02.009_bib11","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jdiacomp.2012.11.005","article-title":"Active- and placebo-controlled dose-finding study to assess the efficacy, safety, and tolerability of multiple doses of ipragliflozin in patients with type 2 diabetes mellitus","volume":"27","author":"Fonseca","year":"2013","journal-title":"J. Diabetes Complicat."},{"key":"10.1016\/j.ejphar.2015.02.009_bib12","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/hep.510310117","article-title":"Peroxisome proliferator-activated receptor gamma transcriptional regulation is involved in platelet-derived growth factor-induced proliferation of human hepatic stellate cells","volume":"31","author":"Galli","year":"2000","journal-title":"Hepatology"},{"key":"10.1016\/j.ejphar.2015.02.009_bib13","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1053\/gast.2002.33666","article-title":"Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro","volume":"122","author":"Galli","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejphar.2015.02.009_bib14","doi-asserted-by":"crossref","first-page":"3263","DOI":"10.1016\/j.bmc.2012.03.051","article-title":"Discovery of ipragliflozin (ASP1941): a novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus","volume":"20","author":"Imamura","year":"2012","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejphar.2015.02.009_bib15","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/35154","article-title":"PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines","volume":"391","author":"Jiang","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2015.02.009_bib16","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1111\/j.1464-5491.2005.01582.x","article-title":"Prevalence of non-alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults","volume":"22","author":"Jimba","year":"2005","journal-title":"Diabet. Med."},{"key":"10.1016\/j.ejphar.2015.02.009_bib17","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1007\/s40262-014-0180-z","article-title":"Clinical pharmacokinetics and pharmacodynamics of the novel SGLT2 inhibitor ipragliflozin","volume":"53","author":"Kadokura","year":"2014","journal-title":"Clin. Pharmacokinet."},{"issue":"3","key":"10.1016\/j.ejphar.2015.02.009_bib18","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/dom.12331","article-title":"Ipragliflozin in combination with metformin for the treatment of Japanese patients with type 2 diabetes: ILLUMINATE, a randomised, double-blind, placebo-controlled study","volume":"17","author":"Kashiwagi","year":"2015","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.ejphar.2015.02.009_bib19","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.bbrc.2004.01.038","article-title":"Pioglitazone prevents hepatic steatosis, fibrosis, and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient l-amino acid-defined diet","volume":"315","author":"Kawaguchi","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejphar.2015.02.009_bib20","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.ejphar.2015.02.009_bib21","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/j.1440-1746.1997.tb00450.x","article-title":"Review: nonalcoholic steatohepatitis","volume":"12","author":"Ludwig","year":"1997","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejphar.2015.02.009_bib22","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1053\/gast.2000.9365","article-title":"Ligands of peroxisome proliferator-activated receptor gamma modulate profibrogenic and proinflammatory actions in hepatic stellate cells","volume":"119","author":"Marra","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejphar.2015.02.009_bib23","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1152\/physiol.00010.2007","article-title":"Brain glucose sensing, counterregulation, and energy homeostasis","volume":"22","author":"Marty","year":"2007","journal-title":"Physiology"},{"key":"10.1016\/j.ejphar.2015.02.009_bib24","doi-asserted-by":"crossref","first-page":"450639","DOI":"10.1155\/2013\/450639","article-title":"Nonalcoholic fatty liver disease, diabetes mellitus and cardiovascular disease: newer data","volume":"2013","author":"Mavrogiannaki","year":"2013","journal-title":"Int. J. Endocrinol."},{"issue":"Suppl 1","key":"10.1016\/j.ejphar.2015.02.009_bib25","first-page":"S17","article-title":"Pathophysiology of nonalcoholic steatohepatitis","volume":"40","author":"McCullough","year":"2006","journal-title":"J. Clin. Gastroenterol."},{"key":"10.1016\/j.ejphar.2015.02.009_bib26","doi-asserted-by":"crossref","first-page":"35715","DOI":"10.1074\/jbc.M006577200","article-title":"Peroxisome proliferator-activated receptors and hepatic stellate cell activation","volume":"275","author":"Miyahara","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2015.02.009_bib27","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/j.1872-034X.2010.00769.x","article-title":"Pitavastatin inhibits hepatic steatosis and fibrosis in non-alcoholic steatohepatitis model rats","volume":"41","author":"Miyaki","year":"2011","journal-title":"Hepatol. Res."},{"key":"10.1016\/j.ejphar.2015.02.009_bib28","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/s00125-011-2446-4","article-title":"Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials","volume":"55","author":"Musso","year":"2012","journal-title":"Diabetologia"},{"key":"10.1016\/j.ejphar.2015.02.009_bib29","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1046\/j.1440-1827.1999.00990.x","article-title":"Endogenous liver carcinogenesis in the rat","volume":"49","author":"Nakae","year":"1999","journal-title":"Pathol. Int."},{"issue":"Suppl 1","key":"10.1016\/j.ejphar.2015.02.009_bib30","first-page":"A285","article-title":"Tofogliflozin improves insulin resistance as well as glucose tolerance by ameliorating fatty liver and obesity","volume":"62","author":"Obata","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2015.02.009_bib31","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2337\/db11-1050","article-title":"Brain glucose sensors play a significant role in the regulation of pancreatic glucose-stimulated insulin secretion","volume":"61","author":"Osundiji","year":"2012","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2015.02.009_bib32","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1097\/MCO.0b013e328357f747","article-title":"Vitamin E and nonalcoholic fatty liver disease","volume":"15","author":"Pacana","year":"2012","journal-title":"Curr. Opin. Clin. Nutr. Metab. Care"},{"key":"10.1016\/j.ejphar.2015.02.009_bib33","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/hep.20012","article-title":"A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis","volume":"39","author":"Promrat","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.ejphar.2015.02.009_bib34","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/0009-9120(96)00003-6","article-title":"A simplified method for the analysis of hydroxyproline in biological tissues","volume":"29","author":"Reddy","year":"1996","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.ejphar.2015.02.009_bib35","first-page":"294","article-title":"Hepatic fibrosis","volume":"5","author":"Rojkind","year":"1976","journal-title":"Prog. Liver Dis."},{"key":"10.1016\/j.ejphar.2015.02.009_bib36","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2133\/dmpk.DMPK-12-RG-082","article-title":"Safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in healthy Japanese subjects","volume":"28","author":"Sarashina","year":"2013","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.ejphar.2015.02.009_bib37","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1053\/S1542-3565(03)00198-8","article-title":"Effect of pioglitazone on biochemical indices of non-alcoholic fatty liver disease in upper body obesity","volume":"1","author":"Shadid","year":"2003","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"Suppl 1","key":"10.1016\/j.ejphar.2015.02.009_bib38","first-page":"S399","article-title":"The effect of ipragliflozin on the total glucose turnover after OGTT in healthy subjects and patients with type 2 diabetes mellitus","volume":"56","author":"Smulders","year":"2013","journal-title":"Diabetologia"},{"key":"10.1016\/j.ejphar.2015.02.009_bib39","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s00210-011-0713-z","article-title":"Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo","volume":"385","author":"Tahara","year":"2012","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"10.1016\/j.ejphar.2015.02.009_bib40","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1254\/jphs.12089FP","article-title":"Antidiabetic effects of SGLT2-selective inhibitor ipragliflozin in streptozotocin\u2013nicotinamide-induced mildly diabetic mice","volume":"120","author":"Tahara","year":"2012","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.ejphar.2015.02.009_bib41","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.ejphar.2013.05.014","article-title":"Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice","volume":"715","author":"Tahara","year":"2013","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2015.02.009_bib42","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1111\/jphp.12223","article-title":"Effects of sodium\u2013glucose cotransporter 2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocin-induced type 1 diabetic rats","volume":"66","author":"Tahara","year":"2014","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejphar.2015.02.009_bib43","first-page":"235","article-title":"The peroxisome proliferator-activated receptor-gamma agonist, pioglitazone, inhibits fat accumulation and fibrosis in the livers of rats fed a choline-deficient, l-amino acid-defined diet","volume":"32","author":"Uto","year":"2005","journal-title":"Hepatol. Res."},{"key":"10.1016\/j.ejphar.2015.02.009_bib44","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1152\/physrev.00055.2009","article-title":"Biology of human sodium glucose transporters","volume":"91","author":"Wright","year":"2011","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.ejphar.2015.02.009_bib45","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.cld.2013.09.018","article-title":"Obesity-associated nonalcoholic fatty liver disease","volume":"18","author":"Yilmaz","year":"2014","journal-title":"Clin. Liver Dis."},{"key":"10.1016\/j.ejphar.2015.02.009_bib46","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ejphar.2014.01.040","article-title":"SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats","volume":"727","author":"Yokono","year":"2014","journal-title":"Eur. J. Pharmacol."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299915001041?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299915001041?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,24]],"date-time":"2018-09-24T21:51:53Z","timestamp":1537825913000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299915001041"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":46,"alternative-id":["S0014299915001041"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2015.02.009","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ipragliflozin, an SGLT2 inhibitor, exhibits a prophylactic effect on hepatic steatosis and fibrosis induced by choline-deficient l-amino acid-defined diet in rats","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2015.02.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}